GR1007368B - Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας - Google Patents

Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας

Info

Publication number
GR1007368B
GR1007368B GR20100100308A GR20100100308A GR1007368B GR 1007368 B GR1007368 B GR 1007368B GR 20100100308 A GR20100100308 A GR 20100100308A GR 20100100308 A GR20100100308 A GR 20100100308A GR 1007368 B GR1007368 B GR 1007368B
Authority
GR
Greece
Prior art keywords
treatment
pharmaceutical solutions
drinkable
dementia symptoms
drinkable pharmaceutical
Prior art date
Application number
GR20100100308A
Other languages
English (en)
Inventor
Γεωργιος Λιολιος
Αγγελος Καρατζας
Ηλιας Κοτσιανης
Original Assignee
Alapis Α.Β.Ε.Ε.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alapis Α.Β.Ε.Ε., filed Critical Alapis Α.Β.Ε.Ε.,
Priority to GR20100100308A priority Critical patent/GR1007368B/el
Priority to PCT/EP2010/061065 priority patent/WO2011147471A1/en
Publication of GR1007368B publication Critical patent/GR1007368B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Σταθερά πόσιμα φαρμακευτικά διαλύματα τα οποία εύκολα μπορούν να μορφοποιηθούν σε πόσιμες σταγόνες, και τα οποία περιλαμβάνουν δονεπεζίλη ή φαρμακευτικά αποδεκτά άλατα αυτής ως δραστικό συστατικό και έναν συνδυασμό πολυαιθυλενογλυκόλης 400 (PEG 400), αιθανόλης και προπυλενογλυκόλης.
GR20100100308A 2010-05-27 2010-05-27 Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας GR1007368B (el)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GR20100100308A GR1007368B (el) 2010-05-27 2010-05-27 Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας
PCT/EP2010/061065 WO2011147471A1 (en) 2010-05-27 2010-08-06 Antidementia oral pharmaceutical solutions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20100100308A GR1007368B (el) 2010-05-27 2010-05-27 Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας

Publications (1)

Publication Number Publication Date
GR1007368B true GR1007368B (el) 2011-08-02

Family

ID=43428623

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20100100308A GR1007368B (el) 2010-05-27 2010-05-27 Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας

Country Status (2)

Country Link
GR (1) GR1007368B (el)
WO (1) WO2011147471A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104958254A (zh) * 2015-06-27 2015-10-07 万特制药(海南)有限公司 一种盐酸多奈哌齐口服溶液及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
KR100746753B1 (ko) 1998-08-28 2007-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 고미 등을 경감한 의약조성물
DK1086706T3 (da) 1999-03-31 2004-03-08 Eisai Co Ltd Stabiliserede sammensætninger indeholdende nootropiske lægemidler
EP1311272B1 (en) 2000-03-03 2006-11-22 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent

Also Published As

Publication number Publication date
WO2011147471A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
BR112012017488A2 (pt) "dispositivo"
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
IN2015DN01156A (el)
MX2010009222A (es) Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
JO3343B1 (ar) أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
GB201211298D0 (en) Learning motivation improvers
PH12013500472A1 (en) Piperidinyl-substituted lactams as gpr119 modulators
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
TW201144301A (en) Processes for preparing linezolid
PH12015501115B1 (en) Learning and memory improver
MX2014014308A (es) Pirrolidino heterociclos.
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
UA103290C2 (ru) Фармацевтическая композиция ибупрофена для инъекции
UA105944C2 (uk) Комбінація теоброміну з деконгестантом і її застосування для лікування кашлю
GR1007368B (el) Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας
MX2012007393A (es) Composicion farmaceutica de disolucion rapida comprendiendo lornoxicam.
WO2015044434A3 (de) FLUOR-9-METHYL-ß-CARBOLINE
WO2013038200A3 (en) Neurodevelopmental disorders

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20110916

ML Lapse due to non-payment of fees

Effective date: 20131204